Distribution and load of amyloid-b pathology in Parkinson disease and dementia with lewy bodies

Journal of Neuropathology and Experimental Neurology

Volumn 75, Issue 10, 2016, Pages 936-945

  Hepp, Dagmar H ^a,b   Vergoossen, Dana L E ^a   Huisman, Evelien ^a   Lemstra, Afina W ^b   Bank, Netherlands Brain ^c   Berendse, Henk W ^d   Rozemuller, Annemieke J ^b   Foncke, Elisabeth M J ^b   Van De Berg, Wilma D J ^a  

^a Section Quantitative Morphology   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^d NONE

Author keywords

Dementia with Lewy bodies; Neuropathology; Parkinson disease; Parkinson disease with dementia; Thal phases; Synuclein; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN;

AGED; AMYGDALA; AMYLOIDOSIS; ARTICLE; AUTOPSY; BRAIN CORTEX; BRAIN REGION; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; ENTORHINAL CORTEX; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGING SYSTEM; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; PARKINSON DISEASE; PARKINSON DISEASE WITH DEMENTIA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PUTAMEN; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SENILE PLAQUE; SUBCORTEX; TEMPORAL CORTEX;

EID: 84995609193     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1093/jnen/nlw070     Document Type: Article

References (60)

1. Halliday GM, Holton JL, Revesz T, et al. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 2011;122:187-204
2. Goedert M, Spillantini MG, Del TK, et al. 100 years of Lewy pathology. Nat Rev Neurol 2013;9:13-24
3. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 2005;65:1863-72
4. Lucetti C, Logi C, Del DP, et al. Levodopa response in dementia with lewy bodies: A 1 year follow-up study. Parkinsonism Relat Disord 2010; 16:522-6
5. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22: 1689-707
6. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007;68:812-9
7. Aarsland D, Ballard CG, Halliday G. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?. J Geriatr Psychiatry Neurol 2004;137-45
8. Halliday GM, McCann H. The progression of pathology in Parkinson's disease. Ann N Y Acad Sci 2010;1184:188-95
9. Horvath J, Herrmann FR, Burkhard PR, et al. Neuropathology of dementia in a large cohort of patients with Parkinson's disease. Parkinsonism Relat Disord 2013;19:864-8
10. Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 2001;102:355-63
11. Compta Y, Parkkinen L, O'Sullivan SS, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain 2011;134:1493-505
12. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000;54:1916-21
13. Bertrand E, Lechowicz W, Szpak GM, et al. Limbic neuropathology in idiopathic Parkinson's disease with concomitant dementia. Folia Neuropathol 2004;42:141-50
14. Parkkinen L, Kauppinen T, Pirttila T, et al. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 2005;57:82-91
15. Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012;72:587-98
16. Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71:903-10
17. Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79:1331-8
18. Gomperts SN, Locascio JJ, Marquie M, et al. Brain amyloid and cognition in Lewy body diseases. Mov Disord 2012;27:965-73
19. Tsuboi Y, Uchikado H, Dickson DW. Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology. Parkinsonism Relat Disord 2007;13(Suppl 3):S221-4
20. Tsuboi Y, Dickson DW. Dementia with Lewy bodies and Parkinson's disease with dementia: Are they different?. Parkinsonism Relat Disord 2005;11(Suppl 1):S47-51
21. Jellinger KA, Attems J. Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?. Acta Neuropathol 2006;112:253-60
22. Halliday GM, Song YJ, Harding AJ. Striatal beta-amyloid in dementia with Lewy bodies but not Parkinson's disease. J Neural Transm 2011; 118:713-9
23. Ballard C, Ziabreva I, Perry R, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006; 67:1931-4
24. Fujishiro H, Iseki E, Higashi S, et al. Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia. Neurosci Lett 2010;486:19-23
25. Walker L, McAleese KE, Thomas AJ, et al. Neuropathologically mixed Alzheimer's and Lewy body disease: Burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol 2015; 129:729-48
26. Halliday G, Hely M, Reid W, et al. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008;115:409-15
27. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psych 1992;55:181-4
28. Braak H, Del TK, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211
29. Leverenz JB, Hamilton R, Tsuang DW, et al. Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol 2008;18:220-4
30. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59
31. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86
32. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012;8:1-13
33. Thal DR, Rub U, Schultz C, et al. Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol 2000;59:733-48
34. Alafuzoff I, Thal DR, Arzberger T, et al. Assessment of beta-amyloid deposits in human brain: A study of the BrainNet Europe Consortium. Acta Neuropathol 2009;117:309-20
35. Hepp DH, Ruiter AM, Galis Y, et al. Pedunculopontine cholinergic cell loss in hallucinating Parkinson disease patients but not in dementia with Lewy bodies patients. J Neuropathol Exp Neurol 2013;72:1162-70
36. Tiraboschi P, Attems J, Thomas A, et al. Clinicians' ability to diagnose dementia with Lewy bodies is not affected by beta-amyloid load. Neurology 2015;84:496-9
37. Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): A common pathology associated with human aging. Acta Neuropathol 2014;128:755-66
38. Kovacs GG, Ferrer I, Grinberg LT, et al. Aging-related tau astrogliopathy (ARTAG): Harmonized evaluation strategy. Acta Neuropathol 2016;131: 87-102
39. Duyckaerts C, Braak H, Brion JP, et al. PART is part of Alzheimer disease. Acta Neuropathol 2015;129:749-56
40. Aho L, Parkkinen L, Pirttila T, et al. Systematic appraisal using immunohistochemistry of brain pathology in aged and demented subjects. Dement Geriatr Cogn Disord 2008;25:423-32
41. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351-7
42. Ruffmann C, Calboli FC, Bravi I, et al. Cortical Lewy bodies and Abeta burden are associated with prevalence and timing of dementia in Lewy body diseases. Neuropathol Appl Neurobiol 2015 Nov 3 doi: 10.1111/nan.12294. [Epub ahead of print]
43. Kalaitzakis ME, Graeber MB, Gentleman SM, et al. Striatal betaamyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol 2008;67:155-61
44. Goldman JG, Williams-Gray C, Barker RA, et al. The spectrum of cognitive impairment in Lewy body diseases. Mov Disord 2014;29:608-21
45. Noe E, Marder K, Bell KL, et al. Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Mov Disord 2004;19:60-7
46. Park KW, Kim HS, Cheon SM, et al. Dementia with Lewy Bodies versus Alzheimer's Disease and Parkinson's Disease Dementia: A Comparison of Cognitive Profiles. J Clin Neurol 2011;7:19-24
47. Tam CW, Burton EJ, McKeith IG, et al. Temporal lobe atrophy on MRI in Parkinson disease with dementia: A comparison with Alzheimer disease and dementia with Lewy bodies. Neurology 2005;64: 861-5
48. Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer diseaseassociated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006;112:389-404
49. Jellinger KA, Attems J. Cerebral amyloid angiopathy in Lewy body disease. J Neural Transm 2008;115:473-82.
50. Kotzbauer PT, Cairns NJ, Campbell MC, et al. Pathologic accumulation of alpha- synuclein and Abeta in Parkinson disease patients with dementia. Arch Neurol 2012;69:1326-31
51. Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psych 2013;84:1258-64
52. Elobeid A, Rantakomi S, Soininen H, et al. Alzheimer's diseaserelated plaques in nondemented subjects. Alzheimers Dement 2014; 10:522-9
53. Colom-Cadena M, Gelpi E, Charif S, et al. Confluence of alphasynuclein, tau, and beta- amyloid pathologies in dementia with Lewy bodies. J Neuropathol Exp Neurol 2013;72:1203-12
54. Overk CR, Cartier A, Shaked G, et al. Hippocampal neuronal cells that accumulate alpha- synuclein fragments are more vulnerable to Abeta oligomer toxicity via mGluR5-implications for dementia with Lewy bodies. Mol Neurodegener 2014;9:18
55. Lin CL, Cheng YS, Li HH, et al. Amyloid-beta suppresses AMPactivated protein kinase (AMPK) signaling and contributes to alphasynuclein-induced cytotoxicity. Exp Neurol 2015;275P3:84-98
56. Marsh SE, Blurton-Jones M. Examining the mechanisms that link betaamyloid and alpha-synuclein pathologies. Alzheimers Res Ther 2012;4:11
57. Bachhuber T, Katzmarski N, McCarter JF, et al. Inhibition of amyloidbeta plaque formation by alpha-synuclein. Nat Med 2015;21:802-7
58. Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 2008;115: 427-36
59. Kovari E, Gold G, Herrmann FR, et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol 2003;106:83-8
60. Abdelnour C, van Steenoven I, Londos E, et al. Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in Lewy body dementia. Mov Disord 2016 Jun 14. doi: 10.1002/mds.26668. [Epub ahead of print].